Clinicians & Researchers

It's an exciting time in neuroscience.

At Sage, we are originating meaningfully differentiated drug candidates. We want to transform the practice of medicine and how central nervous system (CNS) disorders are treated. Our robust pipeline is focused on CNS indications where there are limited treatment options.

Clinical Trials

Discover clinical trials in areas of interest to your patients.

We are conducting clinical trials in a number of CNS disorders where there is a need for additional treatment options.

Reference Library

Our scientists collaborate with academic laboratories, consult with CNS thought leaders, and publish key results.

Nonclinical Manuscripts

Martinez Botella G, Salituro FG, Harrison BL, et al. Neuroactive Steroids. 2. 3α-Hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1′-yl)-19-nor-5β- pregnan-20-one (SAGE-217): A clinical next generation neuroactive steroid positive allosteric modulator of the (γ-Aminobutyric Acid)A Receptor. J Med Chem. 2017; 60:7810-7819.

Hammond RS, Althaus AL, Ackley MA, et al. Anticonvulsant profile of the neuroactive steroid, SGE-516, in animal models. Epilepsy Res. 2017; 134: 16-25.

Althaus AL, McCarren HS, Alqazzaz A, et al. The synthetic neuroactive steroid SGE-516 reduces status epilepticus and neuronal cell death in a rat model of soman intoxication. Epilepsy Behav. 2017; 68: 22-30.

Modgil A, Parakala ML, Ackley MA, et al. Endogenous and synthetic neuroactive steroids evoke sustained increases in the efficacy of GABAergic inhibition via a protein kinase C-dependent mechanism. Neuropharmacology. 2017; 113: 314-322.

Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). Epilepsia. 2017; 58: 181-221.

Martin BS, Martinez-Botella G, Loya CM, et al. Rescue of deficient amygdala tonic γ-aminobutyric acidergic currents in the Fmr-/y mouse model of fragile X syndrome by a novel γ-aminobutyric acid type A receptor-positive allosteric modulator. J Neurosci Res. 2016; 94: 568-78.

Martinez Botella G, Salituro FG, Harrison BL, et al. Neuroactive Steroids. 1. Positive allosteric modulators of the (γ-aminobutyric acid)A receptor: structure-activity relationships of heterocyclic substitution at C-21. J Med Chem. 2015; 58: 3500-11.

Emnett CM, Eisenman LN, Mohan J, et al. Interaction between positive allosteric modulators and trapping blockers of the NMDA receptor channel. Br J Pharmacol. 2015; 172: 1333-47.

Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Res. 2015; 111: 85-141.

Christian EP, Snyder DH, Song W, et al. EEG-β/γ spectral power elevation in rat: a translatable biomarker elicited by GABA(Aα2/3)-positive allosteric modulators at nonsedating anxiolytic doses. J Neurophysiol. 2015; 113: 116-31.

Linsenbardt AJ, Taylor A, Emnett CM, et al. Different oxysterols have opposing actions at N-methyl-D-aspartate receptors. Neuropharmacology. 2014; 85: 232-42.

Gabriel Martinez-Botella, Michael A. Ackley, Francesco G. Salituro, James J. Doherty, Natural and synthetic neuroactive steroid modulators of GABA and NMDA receptors. Annual Reports in Medicinal Chemistry. 2014; 49: 27-42.

Paul SM, Doherty JJ, Robichaud AJ, et al. The major brain cholesterol metabolite 24(S)-hydroxycholesterol is a potent allosteric modulator of N-methyl-D-aspartate receptors. J Neurosci. 2013; 33: 17290-300.

Clinical and Health Economics and Outcomes Research Manuscripts

Rosenthal ES, Claassen J, Wainwright MS, et al. Brexanolone as adjunctive therapy in super-refractory status epilepticus. Ann Neurol. 2017; 82: 342-352.

Strzelczyk A, Ansorge S, Hapfelmeier J, et al. Costs, length of stay, and mortality of super-refractory status epilepticus: A population-based study from Germany. Epilepsia. 2017; 58: 1533-1541.

Kanes S, Colquhoun H, Gunduz-Bruce H, et al. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet. 2017; 309: 480-489.

Kanes SJ, Colquhoun H, Doherty J, et al. Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression. Hum Psychopharmacol. 2017; 32: e2576.

Vaitkevicius H, Husain AM, Rosenthal ES, et al. First-in-man allopregnanolone use in super-refractory status epilepticus. Ann Clin Transl Neurol. 2017; 4: 411-414.

Beg JM, Anderson TD, Francis K, et al. Burden of illness for super-refractory status epilepticus patients. J Med Econ. 2017; 20: 45-53.